Singapore to Launch Pilot of Ceva’s Avian Influenza Vaccine in Wildlife Collections
Ceva Animal Health has announced a pilot vaccination programme targeting highly pathogenic avian influenza (HPAI) in zoological birds in Singapore, in collaboration with the National Parks Board (NParks), Mandai Wildlife Group and the Ceva Wildlife Research Fund. The initiative will take place within the Mandai Wildlife Reserve parks and is planned to begin in 2026. Selected species, with emphasis on birds of prey and threatened taxa, will receive a next-generation avian influenza vaccine.
The trial will assess Ceva’s most recent vaccine platform, which the company characterises as suitable for a broad range of avian species and formulated against currently circulating HPAI strains. The study will focus on immunogenicity parameters, including antibody responses and the durability of induced protection.
